The DOI matches its Crossref record; 127 of the 128 references it cites were found in a registry or an index.
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease
Open accessAbstract
Psoriasis is a chronic immune-mediated skin and joint disease, with a plethora of comorbidities, characterized by a certain genetic predisposition, and a complex pathogenesis based on the IL-23/IL-17 pathway. There is no doubt that the patients affected by psoriasis are more susceptible to infections as well as that the risk of infection is higher in psoriatic subjects than in the general population. The advent of biotechnological agents on the therapeutic arsenal actually available for the treatment of moderate-to-severe patients, given the fact that the severity of the disease is a predictor of the level of infectious risk, has raised the question of whether these ‘new’ drugs could be considered a safer option and how they can be used in selected cases. Old and newer strategies in cases of chronic infectious conditions are reviewed under the light of clinical trials and other studies present in literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710 · cited 2×
“A study comparing drugs for dermatologic and rheumatologic conditions with infliximab revealed that between 1998 and 2001, a total of 70 cases of active tuberculosis after treatment initiation were reported in the FDA’s Adverse Event Reporting System FAERS [28].”
BackgroundEASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,335 · cited 5×
“The pathogenesis of psoriasis involves a feed-forward mechanism of inflammation, including primarily the T-helper cell type 17 (TH17) and IL-23 pathway [1].”
BackgroundInfluentialThe Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Houben, R. M. G. J., & Dodd, P. J. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002152 · Cited by 2,054 · cited 1×
“Once infected, the individual is at the highest risk of developing TB disease within the first two years but can remain at risk for their lifetime [22].”
BackgroundTubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 632 · cited 1×
“highlighted that the risk of tuberculosis is three to four times higher with the use of monoclonal antibodies (MAbs), such as adalimumab, infliximab and certolizumab, compared with etanercept [33].”
BackgroundAbuabara, K., Azfar, R. S., Shin, D. B., Neimann, A. L., Troxel, A. B., & Gelfand, J. M. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09941.x · Cited by 472 · cited 1×
“Infectious diseases are the second leading cause of death among psoriasis patients receiving therapies for moderate-to-severe disease [14]; however, the mechanism by which psoriasis predisposes to infection is still unclear [13].”
BackgroundCohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., Winthrop, K. L., Charles-Schoeman, C., Thirunavukkarasu, K., DeMasi, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210457 · Cited by 393
Reich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S., Hsu, M.-C., Branigan, P., & Blauvelt, A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31773-8 · Cited by 381 · cited 1×
“No cases of tuberculosis were reported in 534 patients treated with guselkumab included in the ECLIPSE trial [38].”
Background
Cited by
Oxidative Stress and Phototherapy in Atopic Dermatitis: Mechanisms, Role, and Future Perspectives
Borgia, F., Pomi, F. L., Vaccaro, M., Alessandrello, C., Papa, V., & Gangemi, S. (2022) · Biomolecules · doi:10.3390/biom12121904 · Cited by 71
“On this topic, psoriasis is a chronic, immune-mediated inflammatory cutaneous disease, mainly characterized by the presence of erythematous plaques, covered by white scales, especially localized over the extensor zones [73].”
BackgroundPapa, V., Pomi, F. L., Borgia, F., Vaccaro, M., Pioggia, G., & Gangemi, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097956 · Cited by 40
Pomi, F. L., Papa, V., Borgia, F., Vaccaro, M., Pioggia, G., & Gangemi, S. (2024) · Life · doi:10.3390/life14040516 · Cited by 45
“…of its susceptibility attributed to genetic factors, psoriasis makes it mandatory to understand its genetic basis to unravel the disease’s biology, to identify clinical biomarkers, and, above all, to discover new drug targets, with the final aim being to advance toward personalized medicine [82].”
Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies
Cannon, L. A., Pan, A., Kovalick, L. K., Sarkissian, A., & Wu, E. Y. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.02.010 · Cited by 26
Torres, T. R., Brembilla, N. C., Langley, R. G. B., Warren, R. B., Thaçi, D., Kolios, A. G. A., Prinz, J. C., Londoño, Á., Nast, A., Santín, M., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20287 · Cited by 25
“62,80 Remarkably, there were no documented cases of TB reactivation, a fact that reinforces the safety profile of targeted IL-23 inhibitors in patients with LTBI who lacked standard prophylactic care.”
Metadata
- Authors
- Motolese, A., Ceccarelli, M., Macca, L., Li Pomi, F., Ingrasciotta, Y., Nunnari, G., & Guarneri, C.
- Affiliations
- University of Messina (IT)
- Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy C/O A.O.U.P. “Gaetano Martino”, via Consolare Valeria, 1, 98125 Messina, Italy
- Corresponding author
- Guarneri, Claudio
- ORCID
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2022-01-21
- Volume
- 10
- Issue
- 2
- Pages
- 228
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC8869084
- OpenAlex
- W4206700877
- Semantic Scholar
- 4f4aaa7fd82a4adc9410319e95293859c36726c5
- Cited by
- 35
- References
- 128
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 17 · 2022: 6
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- psoriasis, infectious disease risk, IL-23/IL-17 pathway, biologic therapy, drug safety, comorbidities, disease severity, chronic infection, psoriasis treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. https://app.cochat.ai/papers/10.3390/biomedicines10020228
- The paper
- Motolese, A., Ceccarelli, M., Macca, L., Li Pomi, F., Ingrasciotta, Y., Nunnari, G., & Guarneri, C. (2022). Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines. https://doi.org/10.3390/biomedicines10020228
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.